Anders D Hove
CIK 1365618 · last filed 2024-01-31
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ANAC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW YORK, NY 10112
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Oruka Therapeutics, Inc. (ABIO) Delisted | Director | 3,554 | $28.80 | $102.4K | $0 | 5 | 2024-01-31 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Director | 0 | $10.19 | $0 | -$187.53M | 25 | 2016-06-24 |
| EDGE | Director | 103,429 | $51.97 | $5.38M | $4.95M | 1 | 2015-10-08 |
| Adverum Biotechnologies, Inc. (AAVL) Delisted | 10%+ Owner | 2,365,471 | — | — | $61.20M | 1 | 2014-08-07 |
| CDE | Director | 0 | $13.88 | $0 | $0 | 1 | 2012-08-06 |
| WORLD HEART CORP (WHRT) Delisted | Director | 4,055,016 | — | — | $2.00M | 4 | 2011-06-27 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | Director | 0 | — | — | $0 | 4 | 2010-10-28 |
| Chelsea Therapeutics International, Ltd. (CHTP) Delisted | 10%+ Owner | 3,024,253 | — | — | -$3.12M | 1 | 2010-09-22 |
| ALIMERA SCIENCES INC (ALIM) Delisted | Director | 242,867 | $5.54 | $1.35M | $3.37M | 1 | 2010-04-28 |
Recent Filings · Page 3 of 5
43 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-09-16 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Sell (S) | −90,000 | -$2.25M | EDGAR |
| 2014-08-07 | Adverum Biotechnologies, Inc. (AAVL) Delisted | Mixed | +21,289,239 | $61.20M | EDGAR |
| 2013-11-19 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Sell (S) | −150,000 | -$2.11M | EDGAR |
| 2013-06-10 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-09-24 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Sell (S) | −19,273 | -$121.5K | EDGAR |
| 2012-09-18 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Sell (S) | −35,000 | -$227.8K | EDGAR |
| 2012-09-13 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Sell (S) | −25,177 | -$165.9K | EDGAR |
| 2012-08-06 | CDE | Disp (D) | −6,162,744 | $0 | EDGAR |
| 2012-07-05 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Other (J) | −820,550 | $0 | EDGAR |
| 2012-05-31 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.